Brandon West, DO
Family Medicine · Pocatello, IDNPI 1750490660
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,423 of the $6,089 with a category attached, or 89.1%. It is spread thinly across 35 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,881 and has fallen 66.9% since, to $623 in 2025. Among family medicine clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 334 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Neuronetics, Inc.$983
- Lilly USA, LLC$743
- AstraZeneca$507
- Amgen$361
- Novo Nordisk$354
- plus $2K from 29 others
What the payments were for
- Travel & lodging$63911%
- Food & beverage$5,42389%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 80 | $1,233 |
| Neuronetics, Inc. | 2 | $983 |
| Lilly USA, LLC | 54 | $743 |
| AstraZeneca | 33 | $507 |
| Amgen | 23 | $361 |
| Novo Nordisk | 23 | $354 |
| Boehringer Ingelheim | 16 | $214 |
| Pfizer | 10 | $179 |
| GSK | 10 | $150 |
| Xeris Pharmaceuticals, Inc. | 7 | $146 |
| Astellas Pharma US Inc | 6 | $144 |
| Novartis | 8 | $134 |
| Phathom Pharmaceuticals, Inc. | 6 | $101 |
| Vanda Pharmaceuticals Inc. | 5 | $88 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $83 |
| Harmony Biosciences LLC | 5 | $80 |
| Teva Pharmaceuticals USA, Inc. | 5 | $69 |
| Merck | 5 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| Corcept Therapeutics | 3 | $40 |
| Exact Sciences | 3 | $40 |
| Roche Diagnostics Corporation | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Boston Scientific | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Ironshore Pharmaceuticals Inc. | 2 | $27 |
| Johnson & Johnson | 2 | $26 |
| Curonix LLC | 2 | $26 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $17 |
| Adlon Therapeutics L.p. | 1 | $17 |
| Medtronic | 1 | $16 |
| Tris Pharma Inc | 1 | $16 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,089 in reported general payments places this provider in the 95th percentile of 803 family medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 87 | $85,378 |
| FarxigaDapagliflozin Propanediol | 64 | $75,571 |
| MounjaroTirzepatide | 68 | $71,832 |
| Tresiba Flextouch U-200Insulin Degludec | 54 | $65,255 |
| TrulicityDulaglutide | 42 | $51,361 |
| JardianceEmpagliflozin | 42 | $42,562 |
| XareltoRivaroxaban | 40 | $37,896 |
| EliquisApixaban | 28 | $28,129 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $13,718 |
| EntrestoSacubitril/Valsartan | 19 | $12,227 |
| Bydureon BciseExenatide Microspheres | 13 | $10,580 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $8,992 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $8,651 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 28 | $5,911 |
| Levothyroxine Sodium | 402 | $5,689 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $743 | $123,193110 claims |
| Novo NordiskOzempic | $354 | $85,37887 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $507 | $84,22378 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $214 | $48,05553 claims |
| Johnson & JohnsonXarelto | $26 | $37,89640 claims |
| PfizerEliquis | $179 | $28,12928 claims |
| NovartisEntresto | $134 | $12,22719 claims |
| AbbVieArmour Thyroid | $1,233 | $1,17619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 803 family medicine providers in Idaho.
Other family medicine in Pocatello
- Amber FrostPocatello$16K
- Chance ChristensenPocatello$6K
- Andrew ThaynePocatello$5K
- Travis NielsenPocatello$4K
- Kenneth CongerSandpoint$266K
- David ButukMeridian$206K
- Anne BroadwayIdaho Falls$184K
- Timothy McHughMeridian$165K
- Phyllis YouBoise$88K
- Ralph SutherlinSt Maries$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.